ABL1 and acute lymphoblastic leukemia: A phase III study (NCT04530565) is recruiting patients with Ph‐positive ALL to compare the effect of usual treatment of chemotherapy and steroids and an ABL1 inhibitor to the same treatment plus blinatumomab.